

Helena W Rodbard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5357245/publications.pdf>

Version: 2024-02-01

27
papers

2,914
citations

471061

17
h-index

500791

28
g-index

28
all docs

28
docs citations

28
times ranked

2611
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Review of Cardiovascular Therapy, 2008, 6, 343-368.	0.6	423
2	Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 2464-2471.	4.3	305
3	Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes and Endocrinology, 2014, 2, 885-893.	5.5	295
4	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care, 2019, 42, 1147-1154.	4.3	249
5	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology, 2017, 5, 864-876.	5.5	244
6	Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2291-2301.	1.8	225
7	Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care, 2019, 42, 2272-2281.	4.3	225
8	Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care, 2014, 37, 2926-2933.	4.3	222
9	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 2018, 41, 2552-2559.	4.3	177
10	Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. Diabetes Care, 2018, 41, 1009-1016.	4.3	143
11	The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes. Diabetes Care, 2017, 40, 171-180.	4.3	91
12	Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes and Endocrinology, 2014, 2, 30-37.	5.5	74
13	Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: randomized, 18-week, open-label, phase 3 trial (onset 3). Diabetes, Obesity and Metabolism, 2017, 19, 1389-1396.	2.2	40
14	A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1001-1009.	2.2	40
15	Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. Advances in Therapy, 2019, 36, 265-277.	1.3	26
16	Biosynthetic Human Insulin and Insulin Analogs. American Journal of Therapeutics, 2020, 27, e42-e51.	0.5	23
17	The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. Diabetes Technology and Therapeutics, 2018, 20, S2-33-S2-41.	2.4	19
18	Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2019, 21, 471-477.	2.4	17

#	ARTICLE	IF	CITATIONS
19	Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies. <i>Diabetes Care</i> , 2020, 43, 2713-2720.	4.3	15
20	Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. <i>American Journal of Managed Care</i> , 2020, 26, S335-S343.	0.8	14
21	The coâ€œformulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled metaâ€œanalysis of phase III studies in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1585-1592.	2.2	11
22	Sotagliflozin added to optimized insulin therapy leads to <scp>HbA1c</scp> reduction without weight gain in adults with type 1 diabetes: A pooled analysis of <scp>inTandem1</scp> and <scp>inTandem2</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2089-2096.	2.2	9
23	Managing weight and glycaemic targets in people with type 2 diabetesâ€”How far have we come?. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00330.	1.0	9
24	Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412199592.	0.9	5
25	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108870.	1.1	4
26	Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis. <i>Diabetes Therapy</i> , 2019, 10, 177-188.	1.2	2
27	Comment on Edelman et al. AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes. <i>Diabetes Care</i> 2014;37:2132â€”2140. <i>Diabetes Care</i> , 2014, 37, e261-e262.	4.3	1